150 related articles for article (PubMed ID: 16501717)
1. Improving birth dose coverage of hepatitis B vaccine.
Hipgrave DB; Maynard JE; Biggs BA
Bull World Health Organ; 2006 Jan; 84(1):65-71. PubMed ID: 16501717
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of storing hepatitis B vaccine outside the cold chain in the Solomon Islands: Identifying opportunities and barriers to implementation.
Breakwell L; Anga J; Dadari I; Sadr-Azodi N; Ogaoga D; Patel M
Vaccine; 2017 May; 35(21):2770-2774. PubMed ID: 28431814
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B vaccine stored outside the cold chain setting: a pilot study in rural Lao PDR.
Kolwaite AR; Xeuatvongsa A; Ramirez-Gonzalez A; Wannemuehler K; Vongxay V; Vilayvone V; Hennessey K; Patel MK
Vaccine; 2016 Jun; 34(28):3324-30. PubMed ID: 27040399
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a locally produced hepatitis B vaccine with the birth dose stored outside the cold chain in rural Vietnam.
Hipgrave DB; Tran TN; Huong VM; Dat DT; Nga NT; Long HT; Van NT; Maynard JE; Biggs BA
Am J Trop Med Hyg; 2006 Feb; 74(2):255-60. PubMed ID: 16474080
[TBL] [Abstract][Full Text] [Related]
5. Implementation of newborn hepatitis B vaccination--worldwide, 2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1249-52. PubMed ID: 19023261
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
Scott N; Palmer A; Morgan C; Lesi O; Spearman CW; Sonderup M; Hellard M
Lancet Glob Health; 2018 Jun; 6(6):e659-e667. PubMed ID: 29773122
[TBL] [Abstract][Full Text] [Related]
7. Countries' interest in a hepatitis B vaccine licensed for the controlled temperature chain; survey results from African and Western Pacific regions.
Petit D; Tevi-Benissan C; Woodring J; Hennessey K; Kahn AL
Vaccine; 2017 Dec; 35(49 Pt B):6866-6871. PubMed ID: 29132994
[TBL] [Abstract][Full Text] [Related]
8. Maternal reasons for non-receipt of valid Hepatitis B birth dose among mother-infant pairs attending routine immunization clinics, South-east, Nigeria.
Okenwa UJ; Dairo MD; Uba B; Ajumobi O
Vaccine; 2019 Oct; 37(46):6894-6899. PubMed ID: 31562005
[TBL] [Abstract][Full Text] [Related]
9. Perinatal hepatitis B prevention program in Shandong Province, China. Evaluation and progress.
Zhang L; Ko S; Lv J; Ji F; Yan B; Xu F; Xu A
Hum Vaccin Immunother; 2014; 10(9):2755-60. PubMed ID: 25483482
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study).
Gosset A; Diallo MY; Betsem E; Schaeffer L; Meda N; Vray M; Sombie R; Shimakawa Y; Boyer S
Vaccine; 2021 Jul; 39(33):4659-4670. PubMed ID: 34238606
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation.
Cui F; Luo H; Wang F; Zheng H; Gong X; Chen Y; Wu Z; Miao N; Kane M; Hennessey K; Hadler SC; Hutin YJ; Liang X; Yang W
Vaccine; 2013 Dec; 31 Suppl 9():J36-42. PubMed ID: 24331019
[TBL] [Abstract][Full Text] [Related]
12. Implementing the birth dose of hepatitis B vaccine in rural Indonesia.
Creati M; Saleh A; Ruff TA; Stewart T; Otto B; Sutanto A; Clements CJ
Vaccine; 2007 Aug; 25(32):5985-93. PubMed ID: 17604881
[TBL] [Abstract][Full Text] [Related]
13. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP; Morgan C; Howell J; Xiao Y; Spearman CW; Sonderup M; Lesi O; Andersson MI; Hellard ME; Scott N
Lancet Glob Health; 2020 Jul; 8(7):e931-e941. PubMed ID: 32562649
[TBL] [Abstract][Full Text] [Related]
14. Impact of Introducing Hepatitis B Birth Dose Vaccines into the Infant Immunization Program in Burkina Faso: Study Protocol for a Stepped Wedge Cluster Randomized Trial (NéoVac Study).
Tall H; Adam P; Tiendrebeogo ASE; Vincent JP; Schaeffer L; von Platen C; Fernandes-Pellerin S; Sawadogo F; Bokoum A; Bouda G; Ouattara S; Ouédraogo I; Herrant M; Boucheron P; Sawadogo A; Betsem E; Essoh A; Kabore L; Ouattara A; Méda N; Hien H; Gosset A; Giles-Vernick T; Boyer S; Kania D; Vray M; Shimakawa Y
Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34206058
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy.
Wang L; Li J; Chen H; Li F; Armstrong GL; Nelson C; Ze W; Shapiro CN
Bull World Health Organ; 2007 Sep; 85(9):688-94. PubMed ID: 18026625
[TBL] [Abstract][Full Text] [Related]
16. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China.
Wang F; Zhang G; Zheng H; Miao N; Shen L; Wang F; Dong P; Du F; Chen C; Zhang X; Cui F
Vaccine; 2017 Jul; 35(33):4229-4235. PubMed ID: 28651839
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study.
Wei KP; Zhu FC; Liu JX; Yan L; Lu Y; Zhai XJ; Chang ZJ; Zeng Y; Li J; Zhuang H
Vaccine; 2018 Jan; 36(2):256-263. PubMed ID: 29195717
[TBL] [Abstract][Full Text] [Related]
18. Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Sep; 61():768-71. PubMed ID: 23013723
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of hepatitis B mother-to-child transmission prevention and postvaccination serological test results of infants at risk of perinatal transmission in two counties of middle China.
Yonghao G; Pumei D; Jianhui Y; Jin X; Yanyang Z; Zhe W
J Viral Hepat; 2017 Aug; 24(8):687-695. PubMed ID: 28199772
[TBL] [Abstract][Full Text] [Related]
20. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
